Overview

Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Gemcitabine